Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma

worldpharmanewsMay 30, 2019

Tag: FDA , Bayer , marginal zone lymphoma

PharmaSources Customer Service